{"id":43167,"date":"2025-10-13T17:09:35","date_gmt":"2025-10-13T09:09:35","guid":{"rendered":"https:\/\/flcube.com\/?p=43167"},"modified":"2025-10-13T17:09:35","modified_gmt":"2025-10-13T09:09:35","slug":"beihai-biotech-secures-fda-ind-approval-for-first%e2%80%91in%e2%80%91class-peptide%e2%80%91drug-conjugate-bh1621","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43167","title":{"rendered":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621"},"content":{"rendered":"\n<p>China\u2011based <strong>Zhuhai Beihai Biotech Co., Ltd.<\/strong> announced today that its Category\u202f1 innovative drug <strong>BH1621<\/strong> has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BH1621<\/strong> \u2013 a first\u2011in\u2011class (FIC) anti\u2011tumor peptide\u2011drug conjugate that couples a novel tumor\u2011specific peptide to a potent cytotoxic payload.<\/li>\n\n\n\n<li><strong>Targeted Delivery<\/strong> \u2013 engineered to home in on tumor cells, releasing the toxic payload only within malignant tissue, thereby expanding the therapeutic window and minimizing off\u2011target toxicity.<\/li>\n\n\n\n<li><strong>Indication<\/strong> \u2013 intended for the treatment of <strong>advanced solid tumors<\/strong> across multiple cancer types.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-preclinical-highlights\">Preclinical Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Key Finding<\/th><\/tr><\/thead><tbody><tr><td><strong>In\u2011vitro<\/strong><\/td><td>BH1621 dramatically inhibited growth of a panel of human tumor cell lines, outperforming standard cytotoxics by 3\u20135\u00d7 in IC\u2085\u2080 values.<\/td><\/tr><tr><td><strong>In\u2011vivo<\/strong><\/td><td>In mouse xenograft models, BH1621 reduced tumor volume by &gt;70\u202f% with no observable weight loss or organ toxicity.<\/td><\/tr><tr><td><strong>Pharmacodynamics<\/strong><\/td><td>The conjugate maintained a high plasma half\u2011life (\u2248\u202f12\u202fh) while delivering the payload preferentially to the tumor microenvironment.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development Path<\/strong> \u2013 FDA IND clearance enables Beihai Biotech to begin Phase\u202f1 clinical trials in the U.S., opening access to a large oncology market and potential partnership opportunities.<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong> \u2013 The unique peptide\u2011targeting platform differentiates BH1621 from other PDCs and antibody\u2011drug conjugates (ADCs) currently in the pipeline.<\/li>\n\n\n\n<li><strong>Future Pipeline<\/strong> \u2013 Successful IND studies will position Beihai Biotech to pursue additional indications and expand the BH1621 platform across other solid tumors.<\/li>\n<\/ul>\n\n\n\n<p><strong>About Zhuhai Beihai Biotech<\/strong><br>Zhuhai Beihai Biotech Co., Ltd. is a China\u2011listed (Category\u202f1) biotechnology company focused on discovering and developing innovative therapeutics for oncology and other high\u2011need disease areas. The company leverages proprietary peptide chemistry and conjugation technology to create next\u2011generation targeted therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43168,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,1717,16,62],"class_list":["post-43167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-beihai-biotech","tag-cancer","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43167\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43167\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T09:09:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621\",\"datePublished\":\"2025-10-13T09:09:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1305.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Beihai Biotech\",\"Cancer\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43167#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43167\",\"name\":\"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1305.webp\",\"datePublished\":\"2025-10-13T09:09:35+00:00\",\"description\":\"China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43167\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1305.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1305.webp\",\"width\":1080,\"height\":608,\"caption\":\"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43167#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621 - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43167","og_locale":"en_US","og_type":"article","og_title":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621","og_description":"China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.","og_url":"https:\/\/flcube.com\/?p=43167","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-13T09:09:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43167#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43167"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621","datePublished":"2025-10-13T09:09:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43167"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43167#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp","keywords":["ADC \/ XDC","Beihai Biotech","Cancer","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43167#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43167","url":"https:\/\/flcube.com\/?p=43167","name":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43167#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43167#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp","datePublished":"2025-10-13T09:09:35+00:00","description":"China\u2011based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category\u202f1 innovative drug BH1621 has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application. The approval marks a critical milestone for the first\u2011in\u2011class anti\u2011tumor peptide\u2011drug conjugate (PDC) developed exclusively by Beihai Biotech.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43167#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43167"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43167#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp","width":1080,"height":608,"caption":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43167#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beihai Biotech Secures FDA IND Approval for First\u2011In\u2011Class Peptide\u2011Drug Conjugate BH1621"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1305.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43167"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43167\/revisions"}],"predecessor-version":[{"id":43169,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43167\/revisions\/43169"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43168"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}